Advertisement


Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

2025 ASCO Annual Meeting

Advertisement

Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I want to welcome everybody to the 2025 ASCO Annual Meeting. This is, as always, an exciting time in the year for us, when so much new science gets presented. Today, what I’m really excited about—above and beyond the cutting-edge new knowledge that’s being shared at this meeting—is how we’re going to distribute it to maximize impact for patients everywhere. The growth in information is something that we’re all grappling with. The explosion in publications—papers, that is—and information that could truly benefit patients is, I think, well known. The question is: how do we keep up? Even within ASCO, where we generate trusted, vetted, expert-prepared, peer-reviewed guidelines, it can be a problem just to find the information that a busy clinician needs in their day to make sure they are offering their patients the most up-to-date care possible. So thinking about those two related issues—the exploding basis of knowledge and the challenge of navigating to quick, accurate answers that a clinician can trust—the last year for us at ASCO has been an exciting one. We’ve partnered and collaborated with Google Cloud to create the ASCO Guidelines Assistant. And it is exactly what the name says—it’s really a discovery tool. What’s different about it compared to some other chat experiences that members may have had is that its answers to our questions are limited to the content of our guidelines. For every answer it gives, it automatically provides the relevant citation. If a user clicks on it, it shows them the specific guideline, when it was last updated, and it highlights in yellow the specific text within the guideline that supports the statement. So it addresses the question of trust, it addresses the question of discoverability, and it addresses the question of timeliness. We are really excited to be able to offer that to all of our members simply by logging on to the ASCO member app or going directly to the website at asco.org. GA—the name standing for Guidelines Assistant—is a small but really important step, I think, in our continuing journey to bring optimal, high-quality care to patients everywhere.

Related Videos

Issues in Oncology

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well as leukemia, lymphoma, and melanoma, from 2013 to 2022 (Abstract 11025). 

Leukemia

William G. Wierda, MD, PhD, on Fixed-Duration Ibrutinib and Venetoclax in First-Line CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, reviews the final analysis of phase II CAPTIVATE study demonstrating the long-term efficacy and safety of ibrutinib plus venetoclax for previously untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including in patients with high-risk genomic features. The 5.5-year progression-free survival and overall survival rates were 66% and 97%, respectively (Abstract 7036).

Lung Cancer

David R. Spigel, MD, FASCO, on NSCLC Treatment Planning: Role of 14-Gene Molecular Assay

David R. Spigel, MD, FASCO, Chief Scientific Officer of Sarah Cannon Research Institute, reviews data on the role of a 14-gene molecular assay in selecting patients with stage IA–IIA non–small cell lung cancer (NSCLC) as high risk (LBA8027). 

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508). 

Breast Cancer

Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.

Advertisement

Advertisement




Advertisement